Crossmark

Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”

Crossref DOI link: https://doi.org/10.1186/s13722-021-00223-z

Published Online: 2021-03-06

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shulman, Matisyahu http://orcid.org/0000-0002-2941-8895
Weiss, Roger

Rotrosen, John

Novo, Patricia

Costello, Elizabeth

Nunes, Edward V.
Funding

Funding for this research was provided by:

National Institute on Drug Abuse (UG1DA013035, UG1DA0135831)
License Information

Text and Data Mining valid from 2021-03-06

Version of Record valid from 2021-03-06
More Information

Article History

Received: 22 September 2020

Accepted: 6 February 2021

First Online: 6 March 2021

Ethics approval and consent to participate

: Ethics approval for the RDD study has been obtained through the BRANY institutional review board.

: Not applicable.

: EVN served as unpaid consultant to Alkermes, Braeburn-Camurus and Pear Therapeutics and has received in-kind medication for studies from Reckitt/Indivior, Alkermes, and a therapeutic application from Pear Therapeutics for a study. RW has consulted to Takeda Pharmaceuticals, Analgesic Solutions, Astellas Pharma, and Cerevel Therapeutics. JR reports medication for the present study from Indivior and Braeburn, and medication and/or funds for other studies (as principal investigator or investigator) from Indivior and Alkermes. MS, PN, EC all have no competing interests to declare.

Document is current

Any future updates will be listed below